Xlear
United States Updated 9 July 2026
Xlear is a finished-dose manufacturer based in United States. It appears in 2 regulatory filings across 1 regulator, without an active US DMF or CEP on file. Its most recent recorded inspection, by US FDA, closed on 18 March 2022 as VAI.
1
registered plants
1 with an FDA FEI number
2
filings
across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
4 of 4 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 18 March 2022 VAI US FDA
- 10 February 2017 VAI US FDA
- 10 November 2011 VAI US FDA
- 4 February 2010 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| American Fork, United States | 3010166224 |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| DIGEMAPS (DO) | 2 | None |
Comparing suppliers?
Choose your molecules and target markets. Xlear comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 18 March 2022.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability